Rimon Therapeutics Ltd.
This article was originally published in Start Up
Rimon Therapeutics set out to discover polymers that would achieve a therapeutic effect without acting like drugs; that is, they would act locally, wouldn't be metabolized, and wouldn't be soluble. The company has initially focused its product development efforts on wound healing, with two technologies, polymer beads that induce angiogenesis, and a polymer that sequesters matrix metalloproteinases.
You may also be interested in...
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
EURLs have been a critical missing element of the IVDR for assessing the higher-risk class D IVDs. Two new implementing regulations, on fees and tasks, bring them closer to designation.
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?